Bifogade filer
Company announcement no. 14 2018_19
Kurs & Likviditet
Kalender
| 2024-12-04 | Årsstämma 2025 |
| 2024-11-05 | Bokslutskommuniké 2024 |
| 2024-08-30 | Kvartalsrapport 2024-Q3 |
| 2024-05-14 | Kvartalsrapport 2024-Q2 |
| 2024-01-30 | Kvartalsrapport 2024-Q1 |
| 2023-12-14 | Ordinarie utdelning AMBU B 0.00 DKK |
| 2023-12-13 | Årsstämma 2024 |
| 2023-11-08 | Bokslutskommuniké 2023 |
| 2023-08-31 | Kvartalsrapport 2023-Q3 |
| 2023-05-03 | Kvartalsrapport 2023-Q2 |
| 2023-02-07 | Kvartalsrapport 2023-Q1 |
| 2022-12-15 | Ordinarie utdelning AMBU B 0.00 DKK |
| 2022-12-14 | Årsstämma 2023 |
| 2022-11-15 | Bokslutskommuniké 2022 |
| 2022-08-25 | Kvartalsrapport 2022-Q3 |
| 2022-05-10 | Kvartalsrapport 2022-Q2 |
| 2022-02-08 | Kvartalsrapport 2022-Q1 |
| 2021-12-15 | Ordinarie utdelning AMBU B 0.29 DKK |
| 2021-12-14 | Årsstämma 2022 |
| 2021-11-09 | Bokslutskommuniké 2021 |
| 2021-08-17 | Kvartalsrapport 2021-Q3 |
| 2021-05-12 | Kvartalsrapport 2021-Q2 |
| 2021-01-27 | Kvartalsrapport 2021-Q1 |
| 2020-12-10 | Ordinarie utdelning AMBU B 0.29 DKK |
| 2020-12-09 | Årsstämma 2021 |
| 2020-11-11 | Bokslutskommuniké 2020 |
| 2020-08-26 | Kvartalsrapport 2020-Q3 |
| 2020-05-05 | Kvartalsrapport 2020-Q2 |
| 2020-02-04 | Kvartalsrapport 2020-Q1 |
| 2019-12-18 | Ordinarie utdelning AMBU B 0.38 DKK |
| 2019-12-17 | Årsstämma 2020 |
| 2019-11-13 | Bokslutskommuniké 2019 |
| 2019-08-22 | Kvartalsrapport 2019-Q3 |
| 2019-05-01 | Kvartalsrapport 2019-Q2 |
| 2019-01-31 | Kvartalsrapport 2019-Q1 |
| 2018-12-13 | Ordinarie utdelning AMBU B 0.40 DKK |
| 2018-12-12 | Årsstämma 2019 |
| 2018-11-13 | Bokslutskommuniké 2018 |
| 2018-08-23 | Kvartalsrapport 2018-Q3 |
| 2018-05-07 | Kvartalsrapport 2018-Q2 |
| 2018-01-31 | Kvartalsrapport 2018-Q1 |
| 2018-01-03 | Split AMBU B 1:5 |
| 2017-12-14 | Ordinarie utdelning AMBU B 1.85 DKK |
| 2017-12-13 | Årsstämma 2018 |
| 2017-09-30 | Bokslutskommuniké 2017 |
| 2017-08-23 | Kvartalsrapport 2017-Q3 |
| 2017-05-02 | Kvartalsrapport 2017-Q2 |
| 2017-02-01 | Kvartalsrapport 2017-Q1 |
| 2016-12-13 | Ordinarie utdelning AMBU B 1.55 DKK |
| 2016-12-12 | Årsstämma 2017 |
| 2016-09-30 | Bokslutskommuniké 2016 |
| 2016-08-19 | Kvartalsrapport 2016-Q3 |
| 2016-05-03 | Kvartalsrapport 2016-Q2 |
| 2016-01-29 | Kvartalsrapport 2016-Q1 |
| 2015-12-11 | Ordinarie utdelning AMBU B 0.95 DKK |
| 2015-12-10 | Årsstämma 2016 |
| 2015-11-11 | Bokslutskommuniké 2015 |
| 2015-08-19 | Kvartalsrapport 2015-Q3 |
| 2015-05-06 | Kvartalsrapport 2015-Q2 |
| 2015-02-02 | Kvartalsrapport 2015-Q1 |
| 2014-12-23 | Split AMBU B 1:4 |
| 2014-12-18 | Ordinarie utdelning AMBU B 3.75 DKK |
| 2014-12-17 | Årsstämma 2015 |
| 2014-11-13 | Bokslutskommuniké 2014 |
| 2014-08-20 | Kvartalsrapport 2014-Q3 |
| 2014-05-02 | Kvartalsrapport 2014-Q2 |
| 2014-02-04 | Kvartalsrapport 2014-Q1 |
| 2013-12-13 | Ordinarie utdelning AMBU B 1.25 DKK |
| 2013-12-12 | Årsstämma 2014 |
| 2013-09-30 | Bokslutskommuniké 2013 |
| 2013-08-20 | Kvartalsrapport 2013-Q3 |
| 2013-05-02 | Kvartalsrapport 2013-Q2 |
| 2013-02-05 | Kvartalsrapport 2013-Q1 |
| 2012-12-14 | Ordinarie utdelning AMBU B 3.00 DKK |
| 2012-12-13 | Årsstämma 2013 |
| 2012-09-30 | Bokslutskommuniké 2012 |
| 2012-08-23 | Kvartalsrapport 2012-Q3 |
| 2012-05-03 | Kvartalsrapport 2012-Q2 |
| 2012-02-09 | Kvartalsrapport 2012-Q1 |
| 2011-12-16 | Ordinarie utdelning AMBU B 2.00 DKK |
| 2011-12-15 | Årsstämma 2012 |
| 2011-09-30 | Bokslutskommuniké 2011 |
| 2011-08-25 | Kvartalsrapport 2011-Q3 |
| 2011-05-09 | Kvartalsrapport 2011-Q2 |
| 2011-02-07 | Kvartalsrapport 2011-Q1 |
| 2010-12-17 | Ordinarie utdelning AMBU B 2.50 DKK |
| 2009-12-17 | Ordinarie utdelning AMBU B 1.50 DKK |
| 2005-03-01 | Split AMBU B 1:2 |
| 2004-02-10 | Split AMBU B 1:10 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
In Q3, Ambu has achieved solid organic growth of 10% and an EBIT margin before special items of 20.1%. The pipeline has been advanced, US approval of ENT scopes secured, and Ambu is on plan for future launch of the duodenoscope, the cystoscope and next generation aView™ monitor. In terms of commercial infrastructure, Ambu has decided to further invest in and strengthen its largest market by moving to a 100% direct sales organization for pulmonary endoscopy in the US. Financial guidance is revised.
“We have a unique position with our pipeline of Visualization products, and we believe there is an untapped potential to be released by further investments in a direct sales force. Therefore, we have decided to go 100% direct with our aScope products on the US market. We believe that in the years to come, our direct sales force will be able to maximise our revenue growth and our entrance into ENT and urology will benefit from having full control of the sales force. With this change, we will build the largest single-use direct organisation in our most important market globally creating a competitive advantage for Ambu. Our expansion is well under way and will be effective during H1 2019/20. As a result, our full-year guidance for 2018/19 and 2019/20 is changed. In line with our communication in June, we are committed to create significant value for our shareholders in the long-term through strategic investments,” says CEO Juan Jose Gonzalez.
A conference call is being held today, 22 August 2019, at 10.00 (CEST). The conference will be held in English and can be followed online at www.ambu.com/webcastQ32019.
Contacts
Investor relations:
CFO, Michael Højgaard, miho@ambu.com / +45 4030 4349
IR Manager, Nicolai Thomsen, nith@ambu.com / +45 2620 8047
Media:
Morten Huse Eikrem-Jeppesen, morten@pressconnect.dk / +45 5385 0770
Ambu A/S
Baltorpbakken 13
DK-2750 Ballerup
Denmark
Tel.: +45 7225 2000
CVR no.: 63 64 49 19
www.ambu.com
Attachment